Literature DB >> 31223452

Discovery of Selective M4 Muscarinic Acetylcholine Receptor Agonists with Novel Carbamate Isosteres.

Qingyi Yang1, Erik A Lachapelle1, Natasha M Kablaoui1, Damien Webb1, Michael Popiolek2, Sarah Grimwood2, Rouba Kozak2, Rebecca E O'Connor3, John T Lazzaro3, Christopher R Butler1, Lei Zhang1.   

Abstract

It has been hypothesized that selective muscarinic acetylcholine receptor (mAChR) M4 subtype activation could provide therapeutic benefits to a number of neurological disorders while minimizing unwanted cholinergic side effects observed due to nonselective mAChR activation. Given the high sequence and structural homology of the orthosteric binding sites among mAChRs, achieving M4 subtype-selective activation has been challenging. Herein, we describe the discovery of a series of M4 subtype-selective agonists bearing novel carbamate isosteres. Comparison of the isosteres' electrostatic potential isosurface sheds light on key structural features for M4 subtype-selective activation. The identified key features were further illustrated in a proposed receptor-agonist interaction mode.

Entities:  

Year:  2019        PMID: 31223452      PMCID: PMC6580797          DOI: 10.1021/acsmedchemlett.9b00106

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  17 in total

1.  An allosteric enhancer of M₄ muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine.

Authors:  Ditte Dencker; Pia Weikop; Gunnar Sørensen; David P D Woldbye; Gitta Wörtwein; Jürgen Wess; Anders Fink-Jensen
Journal:  Psychopharmacology (Berl)       Date:  2012-05-31       Impact factor: 4.530

2.  Discovery of N-sulfonyl-7-azaindoline derivatives as potent, orally available and selective M(4) muscarinic acetylcholine receptor agonists.

Authors:  Atsushi Suwa; Yasuko Konishi; Yoshiharu Uruno; Kentaro Takai; Tomokazu Nakako; Mutsuko Sakai; Takeshi Enomoto; Yoshiaki Ochi; Harumi Matsuda; Atsushi Kitamura; Yasuaki Uematsu; Akihiko Kiyoshi; Takaaki Sumiyoshi
Journal:  Bioorg Med Chem Lett       Date:  2014-05-09       Impact factor: 2.823

3.  Discovery of N-substituted 7-azaindoline derivatives as potent, orally available M1 and M4 muscarinic acetylcholine receptors selective agonists.

Authors:  Kentaro Takai; Yasunao Inoue; Yasuko Konishi; Atsushi Suwa; Yoshiharu Uruno; Harumi Matsuda; Tomokazu Nakako; Mutsuko Sakai; Hiroyuki Nishikawa; Gakuji Hashimoto; Takeshi Enomoto; Atsushi Kitamura; Yasuaki Uematsu; Akihiko Kiyoshi; Takaaki Sumiyoshi
Journal:  Bioorg Med Chem Lett       Date:  2014-05-10       Impact factor: 2.823

4.  The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction.

Authors:  Pradeep J Nathan; Jeannette Watson; Jesper Lund; Ceri H Davies; Gary Peters; Chris M Dodds; Bridget Swirski; Philip Lawrence; Graham D Bentley; Barry V O'Neill; Jon Robertson; Stephen Watson; Gareth A Jones; Paul Maruff; Rodney J Croft; Marc Laruelle; Edward T Bullmore
Journal:  Int J Neuropsychopharmacol       Date:  2012-08-29       Impact factor: 5.176

5.  Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.

Authors:  Celine Valant; Christian C Felder; Patrick M Sexton; Arthur Christopoulos
Journal:  Mol Pharmacol       Date:  2011-10-11       Impact factor: 4.436

6.  Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

Authors:  Anantha Shekhar; William Z Potter; Jeffrey Lightfoot; John Lienemann; Sanjay Dubé; Craig Mallinckrodt; Frank P Bymaster; David L McKinzie; Christian C Felder
Journal:  Am J Psychiatry       Date:  2008-07-01       Impact factor: 18.112

7.  Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.

Authors:  Carrie K Jones; Ashley E Brady; Albert A Davis; Zixiu Xiang; Michael Bubser; Mohammed Noor Tantawy; Alexander S Kane; Thomas M Bridges; J Phillip Kennedy; Stefania R Bradley; Todd E Peterson; M Sib Ansari; Ronald M Baldwin; Robert M Kessler; Ariel Y Deutch; James J Lah; Allan I Levey; Craig W Lindsley; P Jeffrey Conn
Journal:  J Neurosci       Date:  2008-10-08       Impact factor: 6.167

8.  Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats.

Authors:  Ashley E Brady; Carrie K Jones; Thomas M Bridges; J Phillip Kennedy; Analisa D Thompson; Justin U Heiman; Micah L Breininger; Patrick R Gentry; Huiyong Yin; Satyawan B Jadhav; Jana K Shirey; P Jeffrey Conn; Craig W Lindsley
Journal:  J Pharmacol Exp Ther       Date:  2008-09-04       Impact factor: 4.030

9.  Activation and allosteric modulation of a muscarinic acetylcholine receptor.

Authors:  Andrew C Kruse; Aaron M Ring; Aashish Manglik; Jianxin Hu; Kelly Hu; Katrin Eitel; Harald Hübner; Els Pardon; Celine Valant; Patrick M Sexton; Arthur Christopoulos; Christian C Felder; Peter Gmeiner; Jan Steyaert; William I Weis; K Christopher Garcia; Jürgen Wess; Brian K Kobilka
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

10.  Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.

Authors:  Michael Bubser; Thomas M Bridges; Ditte Dencker; Robert W Gould; Michael Grannan; Meredith J Noetzel; Atin Lamsal; Colleen M Niswender; J Scott Daniels; Michael S Poslusney; Bruce J Melancon; James C Tarr; Frank W Byers; Jürgen Wess; Mark E Duggan; John Dunlop; Michael W Wood; Nicholas J Brandon; Michael R Wood; Craig W Lindsley; P Jeffrey Conn; Carrie K Jones
Journal:  ACS Chem Neurosci       Date:  2014-08-19       Impact factor: 4.418

View more
  2 in total

1.  Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist.

Authors:  Matthew Spock; Trever R Carter; Katrina A Bollinger; Changho Han; Logan A Baker; Alice L Rodriguez; Li Peng; Jonathan W Dickerson; Aidong Qi; Jerri M Rook; Jordan C O'Neill; Katherine J Watson; Sichen Chang; Thomas M Bridges; Julie L Engers; Darren W Engers; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Aaron M Bender
Journal:  ACS Med Chem Lett       Date:  2021-08-02       Impact factor: 4.632

Review 2.  Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Jack Bergman; Andrew Coop
Journal:  Biomedicines       Date:  2022-02-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.